August 18, 2023 News by Patricia Inacio, PhD Disability leads to great costs for patients, society: Real-world data Disability progression in people with multiple sclerosis (MS) significantly reduces their quality of life, affects their ability to work, and represents a major socioeconomic cost, according to real-world data collected from a German MS registry. These results suggest that the use of disease-modifying therapies to slow MS progression…
January 18, 2022 News by Margarida Maia, PhD Gilenya Shows Long-term Efficacy, Safety in Real-world RRMS Study Long-term treatment with Gilenya (fingolimod) in routine clinical practice is safe and effective for relapsing-remitting multiple sclerosis (RRMS), a five-year study in Germany of more than 4,000 patients reported. Over time, relapses in the majority of study patients who continued with Gilenya became less common and less severe,…
September 16, 2021 News by Patricia Inacio, PhD Roche, Temedica Launch Brisa App to Improve Lives of German Patients Temedica, a Munich-based digital health company, has joined efforts with Roche to launch a free mobile app that aims to improve care for people with multiple sclerosis (MS) living in Germany. Available in German only, the Brisa app will make a record of individual disease progression in…
November 1, 2019 News by Iqra Mumal, MSc Study: 40% of SPMS Patients in Italy and Germany Unaware of Diagnosis A new study shows that 40% of patients in Italy and Germany who have Ā secondary progressive multiple sclerosis (SPMS) are not aware of their diagnosis, indicating a need for significant improvement in patient-physician communication.
September 17, 2019 News by Patricia Inacio, PhD #ECTRIMS2019 – Relapses Tied to Greater Medical and Personal Costs in Real-world Data Relapses in people with multiple sclerosis (MS) are associated with greater medical and non-medical costs, according to real-world data from two German observational studies. These findings support early treatment with disease-modifying therapies (DMTs) that help to control disease relapses, its researchers said, as a way of possibly reducing such economic…
September 25, 2014 News by Patricia Silva, PhD Evotec Multiple Sclerosis Drug Studies Receive ā¬5 Million in New Funding Funding for continued research and development into understanding, treating, and eventually curing Multiple Sclerosis continues to accelerate. Evotec AG, aĀ German company that specializes in providing drug discovery resources to pharmaceutical and biotech companies, and learning institutions, has just announced the launch of its line-up of groundbreaking studies intoĀ MSĀ — an…